All News

Top news of the day from across the health care landscape

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

A new report published in the CDC Morbidity and Mortality Weekly Report (MMWR) has linked cases of acute hepatitis A virus (HAV) infections from certain states to person-to-person transmission from drug use or homelessness.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Testing DNA through plasma or urine rather than tissue offers health care providers an alternative method to evaluate potential treatment resistance.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

If approved, avatrombopag (Doptelet) would also be indicated for the treatment of chronic immune thrombocytopenia in patients who have had insufficient response to a previous therapy.

Although malignant melanoma incidence has stabilized or declined in women, melanoma-associated mortality rates have risen among men throughout the world.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Top news of the week from Specialty Pharmacy Times.

The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

An up-to-date analysis of melanoma mortality rates show that deaths among men are rising, but stabilizing or decreasing in women.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Selinexor is indicated for patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

Interferon lambda 4 represents a vulnerability that benefits hepatitis C virus to the detriment of humans.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

Seattle Genetics submitted an application for the expanded use of brentuximab vedotin (Adcetris) in combination with a chemotherapy regimen for patients with peripheral T-cell lymphoma.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years.